Gliquidone , ≥98% , 33342-05-1

Synonym(s):
2-{2-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline

CAS NO.：33342-05-1

Empirical Formula: C27H33N3O6S

Molecular Weight: 527.63

MDL number: MFCD00631870

EINECS: 251-463-2

PRODUCT Properties

• Melting point: 179 °C
• Density: 1.34±0.1 g/cm3(Predicted)
• storage temp.: Inert atmosphere,Room Temperature
• solubility: ≥22.4 mg/mL in DMSO; insoluble in H2O; ≥2.455 mg/mL in EtOH with gentle warming and ultrasonic
• form: powder to crystal
• pka: 5.12±0.10(Predicted)
• color: White to Almost white
• Merck: 14,4443

Description and Uses

Gliquidone is a second generation sulfonylurea that selectively inhibits ATP-sensitive potassium channel currents (IK_ATP) in pancreatic β-cells (IC₅₀s = 0.45, 119.1, and 149.7 μM for HIT-T15 cells, cardiomyocytes, and vascular smooth muscle cells, respectively). It is also a peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC₅₀ = 10 μM in a transactivation assay). Gliquidone (0.2 nmol/g) decreases plasma levels of D-glucose and stimulates insulin release in anesthetized rats. It decreases blood glucose levels, serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) activities, and hepatic lipid peroxidation and increases hepatic glutathione (GSH) levels in a rat model of diabetes induced by streptozotocin (STZ; ) when administered at a dose of 10 mg/kg.

Gliquidone is an anti diabetic agent used in the treatment of hypoglycemia which leads to an increased risk in diabetic cardiovascular disease. Also used in the treatment diabetic nephropathy.

Safety

• Safety Statements: 24/25
• RTECS: DB1584250
• HS Code: 29147000